Showing results (371-380 of 421) with videos related to

Sort By:
Pageof 43
Urology|March 4, 2015
Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade diseaseAshraful Hoque, Song Yao, Cathee Till, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Clinical Chemistry|November 6, 2007
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample biasDale McLerran, William E Grizzle, Ziding Feng, et al.
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
American Heart Journal|December 6, 2021
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE studyShalender Bhasin, A Michael Lincoff, Shehzad Basaria, et al.
World Journal of Urology|January 3, 2012
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative GroupDonna P Ankerst, Andreas Boeck, Stephen J Freedland, et al.
Cancer Medicine|April 25, 2022
Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillanceLauren Brady, Lisa F Newcomb, Kehao Zhu, et al.
The New England Journal of Medicine|April 5, 2013
Intermittent versus continuous androgen deprivation in prostate cancerMaha Hussain, Catherine M Tangen, Donna L Berry, et al.
Clinical Chemistry|November 21, 2007
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancerDale McLerran, William E Grizzle, Ziding Feng, et al.
The Prostate|September 3, 2015
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrenceAaron M Horning, Julius A Awe, Chiou-Miin Wang, et al.
Pageof 43